We posit that since Crk phosphoY251 may serve as a biomarker for aggressive GBM, in the subset of classical GBM patients that show a high level of CrkY251 phosphorylation and low level of Abi1, Imatinib treatment may prove beneficial to reduce invasive properties of tumor and improve overall survival. The gene discussed is ABI1; the disease is glioblastoma.